Elicio Therapeutics, Inc. Debt-to-equity in % from Q3 2021 to Q3 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Elicio Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q3 2021 to Q3 2025.
  • Elicio Therapeutics, Inc. Debt-to-equity for the quarter ending September 30, 2025 was 3.42K %.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)

Elicio Therapeutics, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 3.42K +5.93K Sep 30, 2025
Q2 2025 -735 -988 -391% Jun 30, 2025
Q1 2025 -579 -706 -558% Mar 31, 2025
Q4 2024 -494 -414 -514% Dec 31, 2024
Q3 2024 -2.51K -2.48K -9122% Sep 30, 2024
Q2 2024 253 +267 Jun 30, 2024
Q1 2024 126 +136 Mar 31, 2024
Q4 2023 -80.5 -66.9 -493% Dec 31, 2023
Q3 2023 -27.2 -12.1 -80.6% Sep 30, 2023
Q2 2023 -14.4 +33.1 +69.6% Jun 30, 2023
Q1 2023 -9.59 +850 +98.9% Mar 31, 2023
Q4 2022 -13.6 -111 -114% Dec 31, 2022
Q3 2022 -15.1 -209 -108% Sep 30, 2022
Q2 2022 -47.5 Jun 30, 2022
Q1 2022 -860 Mar 31, 2022
Q4 2021 97.3 Dec 31, 2021
Q3 2021 194 Sep 30, 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.